There are over 7000 new medicines in development: without Intellectual Property this simply would not be possible
Joe Jimenez, Novartis CEO and EFPIA President discusses the critical importance of protecting Intellectual Property
Interview with Paul van Arkel, Chair of the EFPIA Healthcare Systems Working Group; Head of Corporate Strategy and Healthcare Systems, Novartis.
Pharmaceutical companies are investing 6x more in R&D than the EU’s 2020 R&D intensity target of 3%.
Throughout the labour market, 5 European jobs are supported for each role created by the pharmaceutical industry.